New vial presentations of Bivigam® (immune globulin, [human] – 10% liquid) and Nabi-HB® (hepatitis B immune globulin [human]) have been made available by ADMA Biologics.
Bivigam is indicated for the treatment of primary humoral immunodeficiency which includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. The product is now available as a 10% liquid in a new 100mL vial, in addition to the 50mL vial.
Nabi-HB is indicated for the treatment of acute exposure to blood containing hepatitis B surface antigen (HBsAg), perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute hepatitis B virus infection. The product is now available in a new 1mL vial as well as a 5mL vial.
“We anticipate the broader suite of Bivigam and Nabi-HB vial configurations will help in providing more targeted dosing levels, minimize drug wastage and allow ADMA’s IG products to have vial presentations in line with competitor offerings,” said Adam Grossman, President and CEO of ADMA.
ADMA Biologics announces commercial availability of expanded vial size offerings for BIVIGAM® and NABI-HB®. News release. ADMA Biologics, Inc. Accessed August 9, 2021. https://www.globenewswire.com/news-release/2021/08/09/2276941/33130/en/ADMA-Biologics-Announces-Commercial-Availability-of-Expanded-Vial-Size-Offerings-for-BIVIGAM-and-NABI-HB.html.
This article originally appeared on MPR